Given that it's one of the world's largest drugmakers, it's reasonable to think that Viatris (NASDAQ: VTRS) could be a reliable wealth building stock. One was the drug manufacturer, Mylan, and the other was Pfizer's generics manufacturing business unit, Upjohn. The merger in November 2020 between the pair left a lot of lingering questions about the prospects for Viatris' performance, however.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting